LumiThera said March 3 that Diopsys is now a wholly-owned subsidiary. The acquisition is expected to create a complementary diagnosis and monitoring platform to LumiThera’s Valeda treatment platform.
The addition of Diopsys’ U.S. sales team will combine with LumiThera’s European Union sales team.
